ArticleJournal of materials science. Materials in medicine2026
Resveratrol-loaded chitosan nanoparticles and adipose-derived stem cell-conditioned medium for liver protection against ischemia-reperfusion injury.
Article in Journal of materials science. Materials in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemia-reperfusion injury (IRI) continues to be a significant obstacle in liver transplantation and often results in graft dysfunction and suboptimal outcomes after transplantation. The current preservation solutions, such as the University of Wisconsin (UW) solution, provide limited protection against oxidative stress, inflammation, and apoptosis. The present study was undertaken to design and test a bioactive preservation solution supplemented with resveratrol-loaded chitosan nanoparticles (Resv-CNPs) and adipose-derived stem cell conditioned medium (ASC-CM) to achieve hepatoprotection during IRI. Resv-CNPs were synthesized using the ionic gelation method and characterized for encapsulation efficiency, release profile, and antioxidant activity. HepG2 cells were exposed to an in vitro IRI model, which involved 24h cold ischemia in UWCM solution followed by 48h reperfusion. Cell viability was evaluated by MTT assay, and ALT, AST, LDH, HMGB1, IL-1β, and IL-6 were measured by ELISA. An in vivo rat model was used to validate the hepatic preservation effect after 24h of cold storage in different solutions. Histopathological changes were assessed by H&E staining and Suzuki scoring. Resv-CNPs had an encapsulation efficiency of 46.21±7.12%, and it showed a biphasic release pattern. The drug release from nanoparticles could provide sustained release of resveratrol for up to 72h. Free resveratrol and Resv-CNPs showed excellent DPPH radical scavenging activity. UWCM supplemented with Resv-CNPs dose-dependently increased hepatocyte viability and significantly decreased injury and inflammatory markers compared to free resveratrol and blank nanoparticles in vitro. In vivo, livers preserved with UWCM + Resv-CNPs showed decreased necrosis, reduced liver injury markers, better architecture, and lower Suzuki scores. The incorporation of Resv-CNPs and ASC-CM into the UW solution provided strong antioxidant, anti-inflammatory, and anti-apoptotic protection against hepatic IRI. This next-generation preservation formulation may improve graft quality, extend storage time, and have the potential to enhance transplantation outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.